Strong cation Exchanger (BCX) cited in a study on a radiopharmaceutical for Neuroendocrine tumor

With a growing interest in clinical applications in recent years, the demand for Gallium-68 (68Ga) has also increased. 68Ga-DOTATATE is used as a radiotracer in Positron Emission Tomography (PET) to detect and evaluate cancer-causing Neuroendocrine tumor (NET) cells. A particle accelerator, Cyclotron, is used in generating radioactive isotope 68Ga at a large scale.

In a recent study published in the Journal of Nuclear Medicine, a group of researchers based in Canada aim to develop a complete high-yield integrated solution for Good Manufacturing Practice (GMP) compliant 68Ga-DOTATATE produced by a Cyclotron. The clinical innocuity and effectiveness were also evaluated to determine whether or not the system can be used as a routine diagnostic tool.

After the target preparation (68Zn) and irradiation procedure, UCT’s CUBCX was employed as a part of 68GaCl3 purification process. While the target preparation was cost-effective, the dosimetry of 68Ga-DOTATATE was comparable to other PET tracers. Clinical examination confirmed that 68Ga from Cyclotron is safe and equivalent to 68Ga produced by a generator.

Citation: Tremblay, Sébastien, et al. “68Ga-DOTATATE Prepared from Cyclotron Produced Gallium-68: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients.” Journal of Nuclear Medicine (2022).

DOI: https://doi.org/10.2967/jnumed.121.263768

Similar Posts